Description
What it is
The extended-release variant of CJC-1295, modified with a Drug Affinity Complex that binds to serum albumin and pushes half-life from minutes to approximately 8 days.
Why it’s studied
The DAC modification produces sustained hormone elevation across multi-day windows — useful for research requiring stable GH and IGF-1 levels rather than natural pulse patterns.
Key research findings
-
Sustained GH and IGF-1 elevation for up to 8 days post-administration (Teichman et al.)
-
Stable serum concentrations documented across multi-week studies
-
Half-life extension confirmed via albumin binding mechanism
